Last updated on November 2017

THE SHP-GCB-402 STUDY FOR GAUCHER DISEASE


Brief description of study

THE SHP-GCB-402 STUDY FOR GAUCHER DISEASE

Detailed Study Description

The SHP-GCB-402 study for Gaucher disease is evaluating the effect velaglucerase alfa (VPRIV®) has on bone pain and bone density in people with type I Gaucher disease.

Clinical Study Identifier: TX14855

Contact Investigators or Research Sites near you

Start Over

Study Coordinator

Gaucher Research Site
Tampa, FL USA

Study Coordinator

Gaucher Research Site
Pittsburgh, PA USA

Study Coordinator

Gaucher Research Site
Rochester, MN USA